Effect of Baseline Geriatric, QOL Assessments on Treatment Outcomes in the GIANT Study
By Efrat Dotan, MD - Last Updated: March 19, 2025At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Efrat Dotan, MD, of Ann B Barshinger Cancer Institute at Lancaster General Health, shared the effects of baseline geriatric and quality of life assessments on treatment outcomes for older patients with metastatic pancreatic cancer.
Advertisement
Advertisement
Related Posts
The phase 3 NEOPAN study has shown that FOLFIRINOX can significantly improve PFS compared with gemcitabine.
Researchers evaluated the use of mFOLFIRINOX for the treatment of patients with resectable pancreatic adenocarcinoma.
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.